João Paulo Barile

Dr. João Paulo Barile

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
PSPaulo de Lima Serrano
Paulo de Lima Serrano
JBJoão Paulo Barile
João Paulo Barile
DSDaniel Seneor
Daniel Seneor
PMPatrícia Marques Mendes
Patrícia Marques Mendes
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Background: Acute hepatic porphyrias (AHPs) represent inherited metabolic disorders of the heme biosynthesis pathway, leading to neurological and systemic impairment. Despite the presence of well-recognized chronic symptoms and signs, acute neurological, both neuromuscular and central neurological complications pose a significant challenge in clinical practice, with a potential risk of greater severity and mortality during acute decompensation episodes of AHPs. Care related to the prescription of medications, considering the risk of porphyrinogenicity, is a major and recurring concern in the acute and chronic management of AHP patients. Infectious clinical complications are significant issues in both outpatient and hospital settings for patients with AHPs. It is crucial to identify therapeutic regimens with the best safety and efficacy profiles for treating such infectious complications in AHP patients. The scarcity of structured knowledge available in guidelines and recommendations often leads to the use of therapeutic options with higher potential risks in treating patients with AHPs. Objectives: This review article aims to provide practical recommendations for managing the most significant infectious complications in clinical practice, with a focus on their impact on the clinical care of patients with AHPs.

6 February 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
PSPaulo de Lima Serrano
Paulo de Lima Serrano
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
JBJoão Paulo Barile
João Paulo Barile
PMPatrícia Marques Mendes
Patrícia Marques Mendes
RCRenan Brandão Rambaldi Cavalheiro
Renan Brandão Rambaldi Cavalheiro
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Secondary hypertension and resistant hypertension may result from potentially treatable acquired or hereditary diseases. Inherited Metabolic Disorders are not routinely included in the differential diagnosis of these contexts associated with hypertension, despite the key importance of diagnosis for several of them which enable the early treatment of them. We aim to discuss the current evidence that indicates that a significant portion of cases of unknown resistant hypertension or suspected secondary hypertension may result from unrecognized Acute Hepatic Porphyria (AHP). Diagnostic work-up for AHP is not routinely performed during the evaluation of patients with resistant or refractory hypertension nor in the investigation of secondary hypertension. AHP may present both with neurological and systemic involvement, and hypertension may be observed as part of acute dysautonomia during acute neurovisceral attacks and as a chronic complication during disease course. As AHP represent a potentially treatable group of metabolic disorders, clinicians should consider the inclusion of this group in the diagnostic evaluation of patients with secondary or resistant hypertension.

24 June 2026 in Muscles
Verified
Journal Article
Open access
PDF file
FAFelipe Azeka
Felipe Azeka
PSPaulo de Lima Serrano
Paulo de Lima Serrano
DSDaniel Delgado Seneor
Daniel Delgado Seneor
SCSophia Calegaretti
Sophia Calegaretti
MPMateus Medeiros Pinheiro
Mateus Medeiros Pinheiro
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Congenital Myasthenic Syndrome represents a complex and heterogeneous group of inherited neuromuscular disorders, which result from variants in genes involved in different pathophysiological mechanisms related to the neuromuscular junction. LRP4 (Low-density lipoprotein receptor-related protein 4) represents one of the most important proteins involved in this complex signaling pathway, acting in a complex with agrin and Muscle Skeletal Receptor Tyrosine Kinase (MuSK) proteins. LRP4 became known to most neurologists due to the description of anti-LRP4 antibody-related Myasthenia Gravis. There are, however, different neurological and neuromuscular disorders that result from pathogenic variants in LRP4 gene, especially a rare and potentially treatable Congenital Myasthenic Syndrome. The authors performed a detailed narrative review, including descriptions of the main pathophysiological, clinical, and therapeutic aspects of LRP4-related Congenital Myasthenic Syndromes.

9 June 2026 in Genes
Verified
Journal Article
Open access
PDF file
DSDaniel Seneor
Daniel Seneor
JBJoão Paulo Barile
João Paulo Barile
PMPatricia Marques Mendes
Patricia Marques Mendes
MOMarco Orsini
Marco Orsini
ESEduardo Mendonça Werneck da Silva
Eduardo Mendonça Werneck da Silva
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Arthrogryposis multiplex congenita (AMC) is a diverse group of conditions characterized by multiple joint contractures. Although individually rare, these disorders are estimated to affect 1 in 3000–5000 live births. Their common pathophysiological mechanism is fetal akinesia, a sustained reduction of fetal movement that may arise from intrinsic disturbances—such as central nervous system malformations, motor neuronopathies, neuropathies, neuromuscular junction defects, congenital myopathies, muscular dystrophies, or metabolic diseases—or from extrinsic factors including uterine constraint, maternal illness, infections, or toxic exposures. Reduced fetal motion leads to relatively uniform clinical manifestations, known as the fetal akinesia deformation sequence (FADS), which is characterized by craniofacial anomalies, pulmonary hypoplasia, growth restriction, and contractures. Currently, AMC is classified by clinical features, such as distal arthrogryposis or lethal congenital contracture syndromes. However, advances in molecular genetics have shown wide variability among conditions classified into the same category. Prognosis is widely variable, ranging from lethal perinatal forms to non-progressive mild conditions. This review discusses AMC etiologies from a topographic standpoint, considering the different levels of the motor system involved, by combining current clinical, genetic, and pathophysiological information.

20 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DSDaniel Delgado Seneor
Daniel Delgado Seneor
LGLucas Henrique de Moura Roger Garcia
Lucas Henrique de Moura Roger Garcia
MGMaria Júlia Tabosa de Carvalh Galvão
Maria Júlia Tabosa de Carvalh Galvão
SGSofia Mônaco Gama
Sofia Mônaco Gama
JBJoão Paulo Barile
João Paulo Barile
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
The enzyme Topoisomerase III alpha (encoded by the gene TOP3A) constitutes an important part of the dissolvasome complex and participates in genomic stability in the nucleus and the mitochondria. Biallelic disease-causing mutations TOP3A are linked to a rare multi-system condition that has some similarities with Bloom syndrome but differentiating characteristics. To further expand the clinical, radiological, and genetic characterization of this condition, we describe a novel patient carrying two previously unreported genetic variants. In addition, a structured review of all previously reported cases in the literature was performed. A total of 27 individuals, among them the newly described patient and patients described in 6 other indexed papers, were included. Two partly overlapping phenotypes were identified: the early-onset type involving prenatal growth retardation, microcephaly, and cardiomyopathy, and the late-onset type involving mitochondrial dysfunction symptoms, such as progressive external ophthalmoplegia, cerebellar ataxia, peripheral neuropathy, as well as distinctive brain magnetic resonance imaging. This study suggests that biallelic truncating mutations relate to early-onset disease while non-truncating genotypes contribute to the late-onset manifestation, which was not previously reported in the literature. Interestingly, the newly described case shared characteristics of both phenotypes. In addition, the detailed characterization of this patient's brain MRI abnormalities provides valuable neuroimaging data that have not been previously reported in detail. The findings support a broad disease spectrum and suggest that variant type may influence disease onset and severity. Recognition of characteristic clinical and radiological features may facilitate diagnosis, particularly in patients with suspected prenatal growth retardation and mitochondrial disorders.

22 August 2024 in Revista Científica do Iamspe
Verified
Journal Article
Open access
PDF file
JBJoão Paulo Barile
João Paulo Barile
RPRoberta Arb Saba Rodrigues Pinto
Roberta Arb Saba Rodrigues Pinto
Introdução: O presente estudo trata de relato de um caso de síndrome da pessoa rígida, ocorrido em hospital terciário em São Paulo, somado a uma revisão de literatura acerca do tema. Objetivos: Relatar caso clínico de síndrome da pessoa rígida em um hospital terciário, descrever seus desfechos clínicos e correlacionar com revisão da literatura. Métodos: Foram analisadas informações priorizando aspectos epidemiológicos, clínicos e terapêuticos, além da etiologia da doença, com o total de 11 artigos científicos utilizados. A paciente referida neste trabalho, apresentava espasmos musculares, em ambos os membros inferiores, com eletroneuromiografia que demonstrava coativação contínua de agonistas e antagonistas das musculaturas paravertebrais e de membros inferiores proximais, além do alto nível de anti-GAD65 (>2.000). Também havia importante transtorno ansioso da paciente e presença de hipotireoidismo. Portanto, trata-se de um caso de síndrome da pessoa rígida plus. Conclusão: Após o diagnóstico deve ser instituído prontamente o tratamento, o que ocorreu na paciente em questão. Foi iniciada terapia sintomática com diazepam, gabapentina, além de iniciada terapia imunomodificadora da doença com pulsoterapia com metilprednisolona, imunoglobulina, rituximab, além de fisioterapia e fisiatria. Portanto, paciente recebeu terapia padrão ouro, como se mostrará na revisão bibliográfica sobre o tema.